S32212, a novel serotonin type 2C receptor inverse agonist/α 2- adrenoceptor antagonist and potential antidepressant: II. A behavioral, neurochemical, and electrophysiological characterization

Journal of Pharmacology and Experimental Therapeutics

Volumn 340, Issue 3, 2012, Pages 765-780

  Dekeyne, Anne ^a   Brocco, Mauricette ^a   Loiseau, Florence ^a   Gobert, Alain ^a   Rivet, Jean Michel ^a   Di Cara, Benjamin ^a   Cremers, Thomas I ^b   Flik, Gunnar ^b   Fone, Kevin C F ^c   Watson, David J G ^c   Papp, Mariusz ^d   Sharp, Trevor ^e   Serres, Florence ^e   Cespuglio, Raymond ^g   Olivier, Berend ^f   Chan, Johnny S W ^f   Lavielle, Gilbert ^a   Millan, Mark J ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^b CHARLES RIVER LABORATORIES   (United States)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d INSTITUTE OF PHARMACOLOGY   (Poland)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f UTRECHT UNIVERSITY   (Netherlands)

^g UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; MESSENGER RNA; N [4 METHOXY 3 (4 METHYLPIPERAZIN 1 YL)PHENYL] 1,2 DIHYDRO 3H BENZO[E]INDOLE 3 CARBOXAMIDE; S 32212; UNCLASSIFIED DRUG;

AGGRESSION; AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BRAIN ELECTROPHYSIOLOGY; CHRONIC STRESS; COGNITION; CONTROLLED STUDY; DRUG MECHANISM; ELECTROENCEPHALOGRAPHY; FEMALE; FORCED SWIMMING TEST; FRONTAL CORTEX; HIPPOCAMPUS; LOCUS CERULEUS; MALE; MAZE TEST; MOUSE; NEUROCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; RAT; RECOGNITION; REM SLEEP; SEXUAL BEHAVIOR; SLOW WAVE SLEEP; SUGAR INTAKE;

ACETYLCHOLINE; ADRENERGIC ALPHA-2 RECEPTOR ANTAGONISTS; AGGRESSION; AMYGDALA; ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; BRAIN CHEMISTRY; BRAIN-DERIVED NEUROTROPHIC FACTOR; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INVERSE AGONISM; HIPPOCAMPUS; INDOLES; MALE; MICE; MOTOR ACTIVITY; NOREPINEPHRINE; PIPERAZINES; RATS; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT2C; SCOPOLAMINE HYDROBROMIDE; SEXUAL BEHAVIOR, ANIMAL; SLEEP; SWIMMING;

EID: 84857346630     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.187534     Document Type: Article

References (76)

1. Adolphs R (2009) The social brain: neural basis of social knowledge. Annu Rev Psychol 60:693-716.
2. 2C receptors. Pharmacol Ther 121:160-173.
3. Boulougouris V and Tsaltas E (2008) Serotonergic and dopaminergic modulation of attentional processes. Prog Brain Res 172:517-542.
4. Breuer ME, Chan JS, Oosting RS, Groenink L, Korte SM, Campbell U, Schreiber R, Hanania T, Snoeren EM, Waldinger M, et al. (2008) The triple monoaminergic reuptake inhibitor DOV 216,303 has antidepressant effects in the rat olfactory bulbectomy model and lacks sexual side effects. Eur Neuropsychopharmacol 18: 908-916.
5. Buyukdura JS, McClintock SM, and Croarkin PE (2011) Psychomotor retardation in depression: biological underpinnings, measurement, and treatment. Prog Neuropsychopharmacol Biol Psychiatry 35:395-409.
6. Carr GV and Lucki I (2011) The role of serotonin receptor subtypes in treating depression: a review of animal studies. Psychopharmacology 213:265-287.
7. Castaneda AE, Tuulio-Henriksson A, Marttunen M, Suvisaari J, and Lönnqvist J (2008) A review on cognitive impairments in depressive and anxiety disorders with a focus on young adults. J Affect Disord 106:1-27. (Pubitemid 350309672)
8. Crespi F (2009) Anxiolytics antagonize yohimbine-induced central noradrenergic activity: a concomitant in vivo voltammetry-electrophysiology model of anxiety. J Neurosci Methods 180:97-105.
9. Cryan JF, Valentino RJ, and Lucki I (2005) Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci Biobehav Rev 29:547-569. (Pubitemid 40755456)
10. de Bodinat C, Guardiola-Lemaitre B, Mocaër E, Renard P, Muñoz C, and Millan MJ (2010) Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov 9:628-642.
11. 2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models. Psychopharmacology 199:549-568.
12. 2Creceptor antagonist, agomelatine, on the rat sleep-wake cycle architecture. Psychopharmacology 205:93-106.
13. Dhir A and Kulkarni SK (2007) Effect of addition of yohimbine (α2-receptor antagonist) to the antidepressant activity of fluoxetine or venlafaxine in the mouse forced swim test. Pharmacology 80:239-243. (Pubitemid 47557257)
14. Di Giovanni G, Esposito E, and Di Matteo V (2010) Role of serotonin in central dopamine dysfunction. CNS Neurosci Ther 16:179-194.
15. 2A-adrenoceptor antagonism. Int J Neuropsychopharmacol 13:1193-1205.
16. El-Ghundi M, O'Dowd BF, and George SR (2007) Insights into the role of dopamine receptor systems in learning and memory. Rev Neurosci 18:37-66.
17. 2A-adrenoceptors: a dialysis comparison to talipexole and quinelorane in the absence of acetylcholinesterase inhibitors. J Pharmacol Exp Ther 305:338-346.
18. Gobert A, Rivet JM, Billiras R, Parsons F, and Millan MJ (2011) Simultaneous quantification of D- versus L-serine, taurine, kynurenate, phosphethanolamine and diverse amino acids in frontocortical dialysates of freely moving rats: differential modulation by N-methyl-D-aspartate (NMDA) and other pharmacological agents. J Neurosci Methods 202:143-157.
19. 2 adrenoceptor blockers on aggressive behavior in mice: implications for the actions of adrenoceptor agents. Psychopharmacology 126:345-350.
20. Hashimoto K (2010) Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions. Psychiatry Clin Neurosci 64:341-357.
21. Hasselmo ME and Sarter M (2011) Modes and models of forebrain cholinergic neuromodulation of cognition. Neuropsychopharmacology 36:52-73.
22. Heisler LK, Zhou L, Bajwa P, Hsu J, and Tecott LH (2007) Serotonin 5-HT2C receptors regulate anxiety-like behavior. Genes Brain Behav 6:491-496. (Pubitemid 47024962)
23. Hull EM and Dominguez JM (2007) Sexual behavior in male rodents. Horm Behav 52:45-55. (Pubitemid 46809862)
24. 2-adrenoceptors in antidepressant action: recent findings from microdialysis studies. Prog Neuropsychopharmacol Biol Psychiatry 28:819-827.
25. Kennedy SH and Rizvi S (2009) Sexual dysfunction, depression, and the impact of antidepressants. J Clin Psychopharmacol 29:157-164.
26. Klinkenberg I, Sambeth A, and Blokland A (2011) Acetylcholine and attention. Behav Brain Res 221:430-442.
27. Kobayashi T, Hayashi E, Shimamura M, Kinoshita M, and Murphy NP (2008) Neurochemical responses to antidepressants in the prefrontal cortex of mice and their efficacy in preclinical models of anxiety-like and depression-like behavior: a comparative and correlational study. Psychopharmacology 197:567-580.
28. 2A-adrenergic receptor knockout mice. Neuroscience 113:289-299.
29. 2A/2C receptors: mutual improvement of sleep, cognition and mood? Eur J Neurosci 29:1795-1809.
30. Lapiz MD and Morilak DA (2006) Noradrenergic modulation of cognitive function in rat medial prefrontal cortex as measured by attentional set shifting capability. Neuroscience 137:1039-1049. (Pubitemid 43053965)
31. 6 receptor antagonists in the social recognition procedure in rats: implication of the frontal cortex. Psychopharmacology 196:93-104.
32. Malkesman O, Pine DS, Tragon T, Austin DR, Henter ID, Chen G, and Manji HK (2009) Animal models of suicide-trait-related behaviors. Trends Pharmacol Sci 30:165-173.
33. Mallick BN, Singh S, and Pal D (2005) Role of α and β adrenoceptors in locus coeruleus stimulation-induced reduction in rapid eye movement sleep in freely moving rats. Behav Brain Res 158:9-21. (Pubitemid 40174707)
34. Marazziti D, Consoli G, Picchetti M, Carlini M, and Faravelli L (2010) Cognitive impairment in major depression. Eur J Pharmacol 626:83-86.
35. Mayers AG and Baldwin DS (2005) Antidepressants and their effect on sleep. Hum Psychopharmacol Clin Exp 20:533-559. (Pubitemid 43056116)
36. 2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie 60:441-460.
37. Millan MJ (2006) Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 110:135-370.
38. 2- adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease. Pharmacol Ther 128:229-273.
39. Millan MJ, Agid Y, Brüne M, Bullmore ET, Carter CS, Clayton NS, Connor R, Davis S, Deakin B, DeRubeis RJ et al. (2012a) Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat Rev Drug Discov 11:141-168.
40. Millan MJ and Brocco M (2003) The Vogel conflict test: procedural aspects, γ-aminobutyric acid, glutamate and monoamines. Eur J Pharmacol 463:67-96. (Pubitemid 36205073)
41. 3 receptor antagonist, S33138, counters cognitive impairments in a range of rodent and primate procedure. Int J Neuropsychopharmacol 13:1035-1051.
42. Millan MJ, Dekeyne A, Papp M, La Rochelle CD, MacSweeny C, Peglion JL, and Brocco M (2001) S33005, a novel ligand at both serotonin and norepinephrine transporters: II. Behavioral profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. J Pharmacol Exp Ther 298:581-591. (Pubitemid 32673408)
43. Millan MJ, Lejeune F, and Gobert A (2000a) Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents. J Psychopharmacol 14:114-138. (Pubitemid 30389486)
44. 2-adrenoceptors: II. Influence on monoaminergic transmission, motor function, and anxiety in comparison with dexmedetomidine and clonidine. J Pharmacol Exp Ther 295:1206-1222.
45. 2- adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization. J Pharmacol Exp Ther 340:750-764.
46. Mitchell PJ (2005) Antidepressant treatment and rodent aggressive behaviour. Eur J Pharmacol 526:147-162.
47. Nair SG and Gudelsky GA (2004) Activation of 5-HT2 receptors enhances the release of acetylcholine in the prefrontal cortex and hippocampus of the rat. Synapse 53:202-207. (Pubitemid 39045538)
48. Noudoost B, Chang MH, Steinmetz NA, and Moore T (2010) Top-down control of visual attention. Curr Opin Neurobiol 20:183-190.
49. Ouyang M, Hellman K, Abel T, and Thomas SA (2004) Adrenergic signaling plays a critical role in the maintenance of waking and in the regulation of REM sleep. J Neurophysiol 92:2071-2082. (Pubitemid 39298664)
50. 2A receptor antagonist exhibits antidepressant-like effects in a battery of rodent behavioural assays: approaching early onset antidepressants. Pharmacol Biochem Behav 94:363-373.
51. Papakostas GI, Homberger CH, and Fava M (2008) A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. J Psychopharmacol 22:843-848.
52. Passani MB and Blandina P (2011) Histamine receptors in the CNS as targets for therapeutic intervention. Trends Pharmacol Sci 32:242-249.
53. Paxinos G and Watson C (1998) The Rat Brain in Stereotaxic Coordinates, Academic Press, London.
54. Pitsikas N and Sakellaridis N (2005) The 5-HT2C receptor antagonist RO 60-0491 counteracts rats' retention deficits in a recognition memory task. Brain Res 1054:200-202. (Pubitemid 41219350)
55. Pittenger C and Duman RS (2008) Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 33:88-109. (Pubitemid 350191319)
56. Razzoli M, Carboni L, and Arban R (2009) Alterations of behavioral and endocrinological reactivity induced by 3 brief social defeats in rats: relevance to human psychopathology. Psychoneuroendocrinology 34:1405-1416.
57. Riedel G, Platt B, and Micheau J (2003) Glutamate receptor function in learning and memory. Behav Brain Res 140:1-47. (Pubitemid 36313239)
58. Robbins TW and Arnsten AF (2009) The neuropsychopharmacology of fronto-executive function: monoaminergic modulation. Annu Rev Neurosci 32:267-287.
59. Rojas-Zamorano JA, Esqueda-Leon E, Jimenez-Anguiano A, Cintra-McGlone L, Mendoza Melendez MA, and Velazquez Moctezuma J (2009) The H1 histamine receptor blocker, chlorpheniramine, completely prevents the increase in REM sleep induced by immobilization stress in rats. Pharmacol Biochem Behav 91:291-294.
60. 2C-adrenoceptor antagonist JP-1302. Br J Pharmacol 150:391-402.
61. Schoevers RA, Van HL, Koppelmans V, Kool S, and Dekker JJ (2008) Managing the patient with co-morbid depression and an anxiety disorder. Drugs 68:1621-1634.
62. Schulte-Herbrü ggen O, Fuchs E, Abumaria N, Ziegler A, Danker-Hopfe H, Hiemke C, and Hellweg R (2009) Effects of escitalopram on the regulation of brain-derived neurotrophic factor and nerve growth factor protein levels in a rat model of chronic stress. J Neurosci Res 87:2551-2560.
63. 2- adrenoceptor antagonist/5-HT-noradrenaline reuptake inhibitor (SNRI), S35966, compared to the SNRI, venlafaxine. Int J Neuropsychopharmacol http://dx.doi.org/10.1017/S1461145711000733.
64. Serretti A and Chiesa A (2009) Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol 29:259-266.
65. 2C receptor antagonist, on the rat sleep profile: a comparison to paroxetine. Pharmacol Biochem Behav 71:599-605.
66. Soumier A, Banasr M, Lortet S, Masmejean F, Bernard N, Kerkerian-Le-Goff L, Gabriel C, Millan MJ, Mocaer E, and Daszuta A (2009) Mechanisms contributing to the phase-dependent regulation of neurogenesis by the novel antidepressant, agomelatine, in the adult rat hippocampus. Neuropsychopharmacology 34:2390-2403.
67. Szegedi A and Schwertfeger N (2005) Mirtazapine: a review of its clinical efficacy and tolerability. Expert Opin Pharmacother 6:631-641. (Pubitemid 40613889)
68. 1Areceptor agonist, alleviates disturbances of novelty discrimination in a social context in rats, a putative model of selective attention deficit. Psychopharmacology 181:134-144.
69. 2Areceptor antagonist EMD 281014 improves delayed matching performance in young and aged rhesus monkeys. Psychopharmacology 179:725-732.
70. Thomas A, Burant A, Bui N, Graham D, Yuva-Paylor LA, and Paylor R (2009) Marble burying reflects a repetitive and perseverative behavior more than novelty-induced anxiety. Psychopharmacology 204:361-373.
71. van Strien NM, Cappaert NL, and Witter MP (2009) The anatomy of memory: an interactive overview of the parahippocampal-hippocampal network. Nat Rev Neurosci 10:272-282.
72. 2 receptor and sexual incentive motivation in male rats. Pharmacol Biochem Behav 83:360-369.
73. Walker MP and Stickgold R (2006) Sleep, memory, and plasticity. Annu Rev Psychol 57:139-166. (Pubitemid 43237230)
74. Willner P (2005) Chronic mild stress (CMS) revisited: consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology 52:90-110.
75. Winters BD, Saksida LM, and Bussey TJ (2008) Object recognition memory: neurobiological mechanisms of encoding, consolidation and retrieval. Neurosci Biobehav Rev 32:1055-1070.
76. 2-Adrenoceptor blockade accelerates the neurogenic, neurotrophic and behavioural effects of chronic antidepressant treatment. J Neurosci 30:1096-1109.